Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | Director | June 20, 2018 | June 22, 2018 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| MyoKardia, Inc.MYOK · Entity 145206 | Director | November 29, 2016 | December 01, 2016 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 29, 2021 | July 01, 2021 |
| Population Health Investment Co., Inc.PHIC · Entity 136038 | Director | January 26, 2021 | January 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 919,876 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 919,876 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Global Blood Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 · Expires 2028-06-19 | Direct | 15,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
MyoKardia, Inc.
Report date November 29, 2016 · Filed December 01, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2016-11-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-11-29 · Other · Disposed 0 · Balance 0 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 6,496 |
Reported balance
Holding disclosure · report date 2016-11-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,496 F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above.
PLIANT THERAPEUTICS, INC.
Report date June 29, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.20 · Expires 2031-06-28 | Direct | 13,286 |
Reported balance
After 2021-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-29 · Grant · Acquired 13,286 · Balance 13,286 F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.
Population Health Investment Co., Inc.
Report date January 26, 2021 · Filed January 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 43,125 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Other · Acquired 43,125 · Balance 43,125 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date March 28, 2019 · Filed April 01, 2019
Section 16 reporting ended · disclosed 2019-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.59 · Expires 2029-03-27 | Direct | 10,000 |
Reported balance
After 2019-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-28 · Grant · Acquired 10,000 · Balance 10,000 F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2022 Filed Aug 18, 2022 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,287 | $11.08 | $14,259.96 |
DisclosureSEC source: 0001209191-22-046731 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209,455 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046731 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039249 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,759 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018590 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,319 Underlying: Common Stock · 3,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,541 | $6.74 | $10,386.34 |
DisclosureSEC source: 0000899243-22-018590 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206,982 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,759 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-018590 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2022 Filed Mar 15, 2022 21:34 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 30,078 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011086 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,078 Underlying: Common Stock · 30,078 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 01:58 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 55,011 | $0.00 Strike: $40.03 | $0.00 |
DisclosureSEC source: 0000899243-21-047032 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,011 Underlying: Common Stock · 55,011 shares Expires 2031-12-01 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 00:37 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 13,286 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-21-044176 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,286 Underlying: Common Stock · 13,286 shares Expires 2031-06-28 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 23:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 38,895 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0000899243-21-025398 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 524 | $71.91 | $37,680.84 |
DisclosureSEC source: 0000899243-21-009369 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,764 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the grant and issuance of 1,521 vested shares of Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009369 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,288 Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 01:45 UTC | Population Health Investment Co., Inc. PHIC · Entity 136038 | OtherClass B Ordinary Shares · Derivative | 43,125 | $250.00 | $10,781,250.00 |
DisclosureSEC source: 0000899243-21-003403 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,125 Underlying: Class A Ordinary Shares · 43,125 shares Expires not disclosed F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2 · kind: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. F2 · price: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2 · balance_after: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,256 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,207 Underlying: Common Stock · 10,256 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,256 | $41.00 | $420,496.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,256 | $17.00 | $174,352.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,463 Underlying: Common Stock · 10,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,000 | $38.00 | $380,000.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 18,200 | $37.50 | $682,500.00 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 15,396 | $37.47 | $576,865.03 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,967 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $37.26 to $37.66 per share. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 65,661 | $36.68 | $2,408,589.93 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,363 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $36.26 to $37.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · balance_after: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 23:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 112,422 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015306 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,422 Underlying: Common Stock · 112,422 shares Expires 2030-06-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010392 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302,291 Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 00:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $36.00 | $720,000.00 |
DisclosureSEC source: 0000899243-20-004375 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,463 Underlying: Common Stock · 10,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. F2 · balance_after: Includes 865 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 82,878 | $0.00 Strike: $37.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029348 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,878 Underlying: Common Stock · 82,878 shares Expires 2029-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionManagement Incentive Units · Derivative | 290,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 12 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 290,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionManagement Incentive Units · Derivative | 418,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 11 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 418,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F6 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionManagement Incentive Units · Derivative | 406,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 10 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 406,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionSeries B Units · Derivative | 66,729 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 9 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Units · Derivative | 132,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 8 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Units · Derivative | 47,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · derivative · entry 7 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 290,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 6 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 418,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 5 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,070,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 406,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 4 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 66,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 132,317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 47,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019138 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 19:27 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $33.59 | $0.00 |
DisclosureSEC source: 0001209191-19-022070 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-27 F1 · derivative.exercise_date: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:46 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,481 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-19-002183 · doc4.xml · derivative · entry 6 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,481 shares Expires 2019-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:46 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,835 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-19-002183 · doc4.xml · derivative · entry 5 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,835 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:46 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,607 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-19-002183 · doc4.xml · derivative · entry 4 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,607 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:46 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 45,923 | $5.10 | $234,207.30 |
DisclosureSEC source: 0001209191-19-002183 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Charles Homcy Revocable Trust Disclosed balance after: 165,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 19:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,782 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001209191-18-063579 · doc4.xml · derivative · entry 8 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,782 shares Expires 2018-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 19:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 25,782 | $4.10 | $105,706.20 |
DisclosureSEC source: 0001209191-18-063579 · doc4.xml · nonDerivative · entry 4 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Charles Homcy Revocable Trust Disclosed balance after: 119,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 19:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,828 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001209191-18-063579 · doc4.xml · derivative · entry 7 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,782 Underlying: Common Stock · 39,828 shares Expires 2018-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2018. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 19:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,390 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001209191-18-063579 · doc4.xml · derivative · entry 6 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,390 shares Expires 2018-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.